A Agilent Technologies Inc.

Agilent Receives Two Scientists’ Choice Awards

(NYSE: A) today announced that two of the company’s instruments have received Scientists’ Choice awards. The Agilent 8890 GC system won for Best New Separations Product, and the Agilent InfinityLab LC/MSD iQ system won for Best New Spectroscopy Product.

SelectScience, an independent, expert-led scientific review, began the Scientists’ Choice Awards in 2007 to enable scientists to voice their opinions on the best laboratory products. Each year, SelectScience invites members to nominate their favorite products in various categories. The awards are based on member votes and recognize the innovation and impact these products have had on the market.

“We are delighted to have received these awards,” said Jacob Thaysen, senior vice president, Agilent and President, Life Sciences and Applied Markets Group (LSAG). “We work hard to create innovative solutions to meet the evolving needs of our customers—particularly the need to simplify their workflows, improve productivity, and reap the benefits of greater connectivity. These awards are a recognition of our continued investment in research and development for the future of the laboratory.”

Both Agilent systems integrate next-generation intelligence, including diagnostic tools and software that ensure pro-active maintenance for maximum uptime and greater sample throughput.

The award for the 8890 reflects the value chromatographers see in these state-of-the-art smart connected technologies. Combined with the system’s flexible configurability, the 8890 is able to meet chromatographic needs today and well into the future.

This is the third award for the InfinityLab LC/MSD iQ system since launching in 2019, a reflection of how the system’s ease of use makes LC/MS technology accessible to chromatographers. The system has previously been recognized by The Analytical Scientist and The Medicine Maker 2019 Innovation awards.

Winners were announced at Pittcon 2020, the world’s largest annual conference and exposition on laboratory science, in Chicago, Illinois.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent . Follow Agilent on , , and .

EN
12/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch